Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
12:35pm, Thursday, 06'th Jun 2024
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio
06:00am, Thursday, 30'th May 2024
While it's always comforting to bank on ideas that the masses believe in, overlooked stocks have their charm too. By targeting enterprises that relatively few investors follow, should the stars align
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
08:00am, Wednesday, 29'th May 2024
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
08:00am, Thursday, 23'rd May 2024
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
12:46pm, Wednesday, 08'th May 2024
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Intra-Cellular Therapies, Inc. (ITCI) Q1 2024 Earnings Call Transcript
01:47pm, Tuesday, 07'th May 2024
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications and Investor Relati
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
09:41am, Tuesday, 07'th May 2024
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago.
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
07:30am, Tuesday, 07'th May 2024
CAPLYTA Q1 2024 net product sales were $144.8 million , compared to $94.7 million for the same period in 2023 , representing a 53% increase
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
08:00am, Tuesday, 30'th Apr 2024
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ne
Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy
04:38am, Tuesday, 30'th Apr 2024
The share price reaction of Intra-Cellular Therapies was not as strong as expected after the positive phase 3 results of Caplyta in major depressive disorder. Positive MDD results represent another de
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
11:07am, Thursday, 25'th Apr 2024
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercializati
3 Biotech Stocks With Skyrocketing Potential: April 2024
11:36am, Wednesday, 24'th Apr 2024
Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.
Intra-Cellular Therapies Prices Public Offering of Common Stock
08:46pm, Wednesday, 17'th Apr 2024
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercializati
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
10:26am, Wednesday, 17'th Apr 2024
Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
